FrancophonIA/ELRC3.0 huggingface dataset:
English: 12 adolescent subjects age 12 up to 18 years were included in the adult study population on prophylactic treatment.
Slovenian: 12 mladostnikov, starih od 12 do 18 let, je bilo vključenih v odraslo študijsko populacijo za profilaktično zdravljenje.
English: ELOCTA can be used in children and adolescents of all ages.
Slovenian: Zdravilo ELOCTA se lahko uporablja pri otrocih in mladostnikih vseh starosti.
English: Do not use this medicine after the expiry date which is stated on the carton and the vial label after “EXP”.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki škatle in viale poleg oznake "EXP".
English: Paediatric population No age-specific differences in adverse reactions were observed between paediatric and adult subjects.
Slovenian: Pediatrična populacija Starostno specifičnih razlik v neželenih učinkih med pediatričnimi in odraslimi osebami niso opazili.
English: The Table 2 presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).
Slovenian: Spodaj predstavljena preglednica 2 je v skladu s klasifikacijo organskih sistemov MedDRA (klasifikacija organskih sistemov in raven prednostnega izraza).
English: The risk of developing inhibitors is correlated to the severity of the disease as well as the exposure to factor VIII, this risk being highest within the first 20 exposure days.
Slovenian: Tveganje za nastanek inhibitorjev je odvisno od resnosti bolezni in izpostavljenosti faktorju VIII, in je največje v prvih 20 dneh izpostavljenosti.
English: Your doctor will perform appropriate laboratory tests to make sure that you have adequate factor VIII levels in your blood.
Slovenian: Zdravnik bo z ustreznimi laboratorijskimi preiskavami zagotovil, da bodo ravni faktorja VIII v vaši krvi ustrezne.
English: ELOCTA is used to replace the missing or deficient factor VIII.
Slovenian: Zdravilo ELOCTA se uporablja za nadomeščanje manjkajočega ali pomanjkljivo delujočega faktorja VIII.
English: In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
Slovenian: Na splošno je treba vse bolnike, zdravljene s koagulacijskim faktorjem VIII, skrbno spremljati glede nastanka zaviralcev z ustreznimi kliničnimi opazovanji in laboratorijskimi preiskavami.
English: For children below the age of 12, more frequent or higher doses may be required (see section 5.1).
Slovenian: Za otroke, stare manj kot 12 let, bodo morda potrebni pogostejši ali večji odmerki (glejte poglavje 5.1).
English: An instructional video on how to prepare and administer ELOCTA is available by scanning the QR code with a smartphone or via the website.
Slovenian: Video z navodili glede priprave in dajanja zdravila ELOCTA je na voljo, ko poskenirate kodo QR s pametnim telefonom ali prek spletne strani.
English: Paediatric population The listed warnings and precautions apply both to adults, children and adolescents.
Slovenian: Navedena opozorila in previdnostni ukrepi veljajo za odrasle, otroke in mladostnike.
English: Prophylaxis regimens:
Slovenian: Profilaktični režimi:
English: Activated factor X converts prothrombin into thrombin.
Slovenian: Aktivirani faktor X pretvori protrombin v trombin.
English: If your or your child's bleeding is not being controlled with ELOCTA, tell your doctor immediately.
Slovenian: Če krvavitev pri vas ali vašem otroku z zdravilom ELOCTA ni obvladana, morate to nemudoma povedati zdravniku.
English: Tables 5 and 6 present the pharmacokinetic parameters calculated from the paediatric data of subjects less than 18 years of age.
Slovenian: V preglednicah 5 in 6 so predstavljeni farmakokinetični parametri, izračunani iz pediatričnih podatkov za osebe, stare manj kot 18 let.
English: No interactions of human coagulation factor VIII (rDNA) with other medicinal products have been reported.
Slovenian: Študij medsebojnega delovanja med humanim koagulacijskim faktorjem VIII (rDNA) z drugimi zdravili niso izvedli.
English: In such cases, it is recommended that a specialised haemophilia centre be contacted.
Slovenian: V takih primerih je priporočljivo, da se posvetujete s specializiranim centrom za hemofilijo.
English: Talk to your doctor if you think that your bleeding is not being controlled with the dose you receive.
Slovenian: Posvetujte se z zdravnikom, če menite, da z odmerkom, ki ga prejemate, vaša krvavitev ni ustrezno nadzorovana.
English: Repeat injection every 8 to 24 hours as necessary until adequate wound healing, then therapy at least for another 7 days to maintain a factor VIII activity of 30% to 60% (IU/dL).
Slovenian: Injiciranje ponavljajte vsakih 8 do 24 ur, kot je potrebno, dokler se rana zadovoljivo ne zaceli, potem nadaljujte zdravljenje še vsaj 7 dni za vzdrževanje aktivnosti faktorja VIII 30 % do 60 % (i.e./dl).
English: ELOCTA can be used for all age groups.
Slovenian: Zdravilo ELOCTA se lahko uporablja za vse starostne skupine.
English: A placental transfer study in mice was conducted (see section 5.3).
Slovenian: Izvedli so študijo prenosa v posteljico pri miših (glejte poglavje 5.3).
English: Please safely dispose of the used needle, any unused solution, the syringe and the empty vial in an appropriate medical waste container as these materials may hurt others if not disposed of properly.
Slovenian: Uporabljeno iglo, vso morebitno neuporabljeno raztopino, injekcijsko brizgo in prazno vialo varno zavrzite v ustrezni vsebnik za medicinske odpadke, saj lahko ti materiali poškodujejo druge osebe, če jih ne odstranite pravilno.
English: It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line without the addition of any exogenous human- or animal-derived protein in the cell culture process, purification or final formulation.
Slovenian: Pridobljen je z rekombinantno DNA tehnologijo v celični liniji humanih embrionalnih ledvičnih celic (HEK - human embryonic kidney) brez dodajanja kakršnih koli eksogenih beljakovin humanega ali živalskega izvora pri postopku celične kulture, prečiščevanja ali končne formulacije zdravila.
English: The factor VIII/von Willebrand factor complex consists of 2 molecules (factor VIII and von Willebrand factor) with different physiological functions.
Slovenian: Kompleks faktorja VIII/von Willebrandovega faktorja sestavljata 2 molekuli (faktor VIII in von Willebrandov faktor) z različnim fiziološkim delovanjem.
English: If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician.
Slovenian: Če se pojavijo simptomi preobčutljivosti, je treba bolnikom svetovati, da nemudoma prenehajo z uporabo zdravila in se posvetujejo z zdravnikom.
English: The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case (see section 5.2).
Slovenian: Količino danega zdravila in pogostnost dajanja vedno določamo glede na klinično učinkovitost pri posameznem bolniku (glejte poglavje 5.2).
English: The time to peak activity is not expected to be delayed.
Slovenian: Ni pričakovati, da bo prišlo do zakasnitve v času do najvišje aktivnosti.
English: ELOCTA (95% CI)
Slovenian: Zdravilo ELOCTA (95-odstotni IZ)
English: The dose of ELOCTA is calculated depending on your body weight and the factor VIII levels to be achieved.
Slovenian: Odmerek zdravila ELOCTA se izračuna na podlagi vaše telesne mase in ravni faktorja VIII, ki jo je treba doseči.
English: Documentation
Slovenian: Dokumentacija
English: Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breast-feeding is not available.
Slovenian: Na podlagi redke pojavnosti hemofilije A pri ženskah podatki o izkušnjah glede uporabe faktorja VIII med nosečnostjo in dojenjem niso na voljo.
English: Note: If you use more than one vial of ELOCTA per injection, each vial should be prepared separately as per the previous instructions (steps 1 to 13) and the solvent syringe should be removed, leaving the vial adapter in place.
Slovenian: Opomba: Če boste uporabili več kot eno vialo zdravila ELOCTA na injekcijo, morate vsako vialo pripraviti posebej v skladu s predhodnimi navodili (koraki 1 do 13) in injekcijsko brizgo z vehiklom odstraniti, nastavek viale pa pustite nameščen.
English: ELOCTA is prepared by recombinant technology without addition of any human- or animal-derived components in the manufacturing process.
Slovenian: Zdravilo ELOCTA se izdeluje s pomočjo rekombinantne tehnologije brez dodajanja kakršnih koli sestavin humanega ali živalskega izvora pri postopku izdelave.
English: The Fc region of human immunoglobulin G1 binds to the neonatal Fc receptor.
Slovenian: Regija Fc humanega imunoglobulina G1 se veže na neonatalni receptor Fc.
English: If you cannot use the prepared ELOCTA solution immediately, it should be used within 6 hours.
Slovenian: Če pripravljene raztopine zdravila ELOCTA ne morete uporabiti takoj, jo morate uporabiti v 6 urah.
English: The following side effects may occur with this medicine.
Slovenian: Pri tem zdravilu se lahko pojavijo naslednji neželeni učinki.
English: If any of these symptoms occur, stop the injection immediately and contact your doctor.
Slovenian: Če se pojavi kateri koli od teh simptomov, takoj prenehajte z injiciranjem in se posvetujte z zdravnikom.
English: Wipe the top of the vial with one of the alcohol swabs (F) provided in the pack, and allow to air dry.
Slovenian: Obrišite zgornji del viale z enim alkoholnim zložencem (F) iz pakiranja in pustite, da se osuši na zraku.
English: Studies to investigate genotoxicity, carcinogenicity, toxicity to reproduction or embryo-foetal development have not been conducted.
Slovenian: Študij za preučitev genotoksičnost, kancerogenosti, vpliva na sposobnost razmnoževanja in embrio fetalnega razvoja niso izvedli.
English: The starting prophylactic regimen consisted of 25 IU/kg on the first day followed by 50 IU/kg on the fourth day.
Slovenian: Začetni profilaktični režim je bil sestavljen iz 25 i.e./kg na prvi dan, ki mu je sledilo 50 i.e./kg na četrti dan.
English: What ELOCTA is and what it is used for What you need to know before you use ELOCTA How to use ELOCTA
Slovenian: Kaj je zdravilo ELOCTA in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo ELOCTA Kako uporabljati zdravilo ELOCTA
English: The vial should be gently swirled until all of the powder is dissolved.
Slovenian: Vialo je treba nežno obračati, dokler se ne raztopi ves prašek.
English: The dose may be adjusted based on patient response in the range of 25 to 65 IU/kg (see section 5.1 and 5.2).
Slovenian: Odmerek se lahko prilagodi glede na bolnikov odziv v razponu od 25 do 65 i.e./kg (glejte poglavji 5.1 in 5.2).
English: ELOCTA pack contains:
Slovenian: Pakiranje zdravila ELOCTA vsebuje:
English: Only the provided infusion set should be used because treatment failure can occur as a consequence of coagulation factor VIII adsorption to the internal surfaces of some injection equipment.
Slovenian: Uporabljati je dovoljeno le priloženi komplet za infundiranje, saj je neuspešnost zdravljenja lahko posledica adsorpcije koagulacijskega faktorja VIII na notranjo površino nekaterih oprem za injiciranje.
English: Pharmacotherapeutic group: antihaemorrhagics, blood coagulation factor VIII, ATC code: B02BD02
Slovenian: Farmakoterapevtska skupina: antihemoragiki, koagulacijski faktor VIII, oznaka ATC: B02BD02
English: In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable.
Slovenian: Še zlasti pri velikih kirurških posegih je skrbno spremljanje nadomestnega zdravljenja z analizo koagulacije (aktivnosti faktorja VIII v plazmi) nepogrešljivo.
English: 6 to <12 years
Slovenian: 6 do < 12 let
English: Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X on phospholipid surfaces.
Slovenian: Aktivirani faktor VIII deluje kot kofaktor aktiviranega faktorja IX in pospeši pretvorbo faktorja X v aktivirani faktor X na fosfolipidnih površinah.
English: The total number of exposure days was 80,848 with a median of 294 (range 1-735) exposure days per subject.
Slovenian: Skupno število dni izpostavljenosti je bilo 80.848 z mediano 294 (razpon 1-735) dni izpostavljenosti na osebo.
English: If you use more ELOCTA than you should
Slovenian: Če ste uporabili večji odmerek zdravila ELOCTA, kot bi smeli
English: What you need to know before you use ELOCTA Do not use ELOCTA:
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo ELOCTA Ne uporabljajte zdravila ELOCTA:
English: The date that the product is removed from refrigeration should be recorded on the carton.
Slovenian: Datum, ko je bilo zdravilo vzeto iz hladilnika, je treba zabeležiti na škatli.
English: 2 Investigator term: vascular pain after injection of ELOCTA
Slovenian: 2 Raziskovalčev izraz: vaskularna bolečina po injiciranju zdravila ELOCTA.
English: Non-clinical data reveal no special hazard for humans based on acute and repeated dose toxicity studies (which included assessments of local toxicity and safety pharmacology).
Slovenian: Predklinični podatki na osnovi študij akutne toksičnosti in toksičnosti pri ponavljajočih odmerkih ne kažejo posebnega tveganja za človeka (to vključuje oceno lokalne toksičnosti in farmakološke varnosti).
English: What ELOCTA is and what it is used for
Slovenian: Kaj je zdravilo ELOCTA in za kaj ga uporabljamo
English: Repeat injection every 8 to 24 hours until threat is resolved.
Slovenian: Injiciranje ponavljajte vsakih 8 do 24 ur, dokler nevarnost ne preneha.
English: Check the expiry date on the ELOCTA carton.
Slovenian: Preverite datum izteka roka uporabnosti na škatli zdravila ELOCTA.
English: Your doctor will calculate your dose of ELOCTA (in International Units or “IU”) depending on your individual needs for factor VIII replacement therapy and on whether it is used for prevention or treatment of bleeding.
Slovenian: ki ga boste prejemali (v mednarodnih enotah ali "i.e."), odvisno od vaših individualnih potreb glede zdravljenja za nadomeščanje faktorja VIII in ali se uporablja za preprečevanje ali za zdravljenje krvavitve.
English: Following a washout period of at least 96 hours (4 days), the subjects received a single dose of 50 IU/kg of ELOCTA.
Slovenian: Po vsaj 96-urnem (4-dnevnem) obdobju izpiranja so osebe prejele enkratni odmerek 50 i.e./kg zdravila ELOCTA.
English: Adverse reactions were monitored for a total of 893.72 subject-years.
Slovenian: Neželene učinke so spremljali za skupaj 893,72 preiskovancev-let.
English: It is strongly recommended that every time that ELOCTA is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the medicinal product.
Slovenian: Močno se priporoča, da se ob vsaki uporabi zdravila ELOCTA pri bolniku zabeleži ime in številka serije zdravila, da se ohranja povezava med bolnikom in serijo zdravila.
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
Slovenian: Za shranjevanje neporabljenega zdravila med uporabo in za pogoje pred uporabo je odgovoren uporabnik.
English: In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.
Slovenian: V nekaterih primerih, zlasti pri mlajših bolnikih, bodo morda potrebni krajši razmiki med odmerki ali višji odmerki.
English: This receptor is expressed throughout life and is part of a naturally occurring pathway that protects immunoglobulins from lysosomal degradation by cycling these proteins back into circulation, resulting in their long plasma half-life.
Slovenian: Ta receptor je izražen vse življenje in je del naravne poti, ki ščiti imunoglobuline pred lizosomsko razgradnjo z vključitvijo teh beljakovin nazaj v obtok, kar podaljša njihov razpolovni čas v plazmi.
English: If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed.
Slovenian: Če niso dosežene pričakovane ravni aktivnosti faktorja VIII v plazmi ali krvavitev ni obvladana z ustreznim odmerkom, je treba opraviti preiskavo za prisotnost zaviralcev faktorja VIII.
English: Other medicines and ELOCTA
Slovenian: Druga zdravila in zdravilo ELOCTA
English: The immunogenicity of ELOCTA was evaluated in the clinical trial programme in 276 previously treated patients with severe haemophilia A (207 adolescents and adult and 69 paediatric patients).
Slovenian: Imunogenost zdravila ELOCTA so ocenili v programu kliničnega preskušanja z 276 predhodno zdravljenimi bolniki s hudo hemofilijo A (207 mladostnikov in odraslih ter 69 pediatričnih bolnikov).
English: Of note, ABR is not comparable between different factor concentrates and between different clinical studies.
Slovenian: Pripomniti je treba, da mediana letne stopnje krvavitev ni primerljiva med različnimi koncentrati faktorja in različnimi kliničnimi študijami.
English: The target factor VIII levels will depend on the severity and location of the bleeding.
Slovenian: Ciljne ravni faktorja VIII so odvisne od resnosti in mesta krvavitve.
English: Contents of the pack and other information What ELOCTA contains
Slovenian: Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo ELOCTA
English: In children below the age of 12, higher doses or more frequent injections may be needed.
Slovenian: Pri otrocih, starih do 12 let, bodo morda potrebni večji odmerki ali pogostejše injiciranje.
English: Weekly prophylaxis: 65 IU/kg
Slovenian: Tedenska profilaksa: 65 i.e./kg
English: Factor VIII is a protein produced naturally in the body and is necessary for the blood to form clots and stop bleeding.
Slovenian: Faktor VIII je beljakovina, ki v telesu naravno nastaja in je potrebna za strjevanje krvi in ustavitev krvavitve.
English: Pharmacokinetic parameters after 50 IU/kg dose of ELOCTA are presented in Tables 3 and 4.
Slovenian: Farmakokinetični parametri po odmerku 50 i.e./kg zdravila ELOCTA so predstavljeni v preglednicah 3 in 4.
English: Hypersensitivity to the active substance (recombinant human coagulation factor VIII, and/or Fc domain) or to any of the excipients listed in section 6.1.
Slovenian: Preobčutljivost na učinkovino (rekombinantni humani koagulacijski faktor VIII in/ali domeno Fc) ali katero koli pomožno snov, navedeno v poglavju 6.1.
English: Out of 67 subjects having completed Study II, 61 enrolled onto Study III (extension study).
Slovenian: Med 67 osebami, ki so končale študijo II, jih je bilo 61 vključenih v študijo III (podaljšek študije).
English: Efmoroctocog alfa binds to neonatal Fc receptor thereby utilising this same naturally occurring pathway to delay lysosomal degradation and allow for longer plasma half-life than endogenous factor VIII.
Slovenian: Efmoroktokog alfa se veže na neonatalni receptor Fc, za kar uporablja to isto naravno pot, da upočasni lizosomsko razgradnjo in omogoči daljši razpolovni čas v plazmi kot endogeni faktor VIII.
English: Do not use this medicine if you notice that it is cloudy or contains visible particles.
Slovenian: Ne uporabljajte tega zdravila, če opazite, da je raztopina motna ali so v njej vidni delci.
English: All pharmacokinetic studies with ELOCTA were conducted in previously treated patients with severe haemophilia A. Data presented in this section were obtained by chromogenic and one-stage clotting assays.
Slovenian: Vse farmakokinetične študije z zdravilom ELOCTA so bile izvedene pri predhodno zdravljenih bolnikih s hudo hemofilijo A. Podatki, predstavljeni v tem poglavju, so bili pridobljeni s pomočjo kromogenih in enostopenjskih strjevalnih preskusov.
English: In patients with existing cardiovascular risk factors, substitution therapy with FVIII may increase the cardiovascular risk.
Slovenian: Pri bolnikih z obstoječimi kardiovaskularnimi dejavniki tveganja lahko nadomestno zdravljenje s FVIII
English: Record on the carton the date that ELOCTA is removed from the refrigerator and set at room temperature.
Slovenian: Na škatlo zabeležite datum, ko zdravilo ELOCTA vzamete iz hladilnika in postavite na sobno temperaturo.
English: This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free'.
Slovenian: To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na vialo, kar v bistvu pomeni „brez natrija“.
English: Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an International Standard for factor VIII in plasma).
Slovenian: Aktivnost faktorja VIII v plazmi izražamo bodisi v odstotkih (glede na normalno humano plazmo) bodisi v mednarodnih enotah (glede na Mednarodni standard za faktor VIII v plazmi).
English: The frequencies in Table 2 below were observed in a total of 276 patients with severe haemophilia A in phase III clinical studies and an extension study with a duration of up to four years.
Slovenian: Pogostnosti v preglednici 2 so opazili pri skupno 276 bolnikih s hudo hemofilijo A v kliničnih študijah faze III in v podaljšku študije, ki je trajala do štiri leta.
English: ELOCTA has no influence on the ability to drive and use machines.
Slovenian: Zdravilo ELOCTA nima vpliva na sposobnost vožnje in upravljanja strojev.
English: The calculation of the required dose of recombinant factor VIII Fc is based on the empirical finding that 1 International Unit (IU) factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/dL.
Slovenian: Izračun potrebnega odmerka rekombinantnega faktorja VIII Fc temelji na empirični ugotovitvi, da 1 mednarodna enota (i.e.) faktorja VIII na kilogram telesne mase poveča plazemsko aktivnost faktorja VIII za 2 i.e./dl.
English: No effects on ability to drive or use of machines have been observed.
Slovenian: Vpliva na sposobnost vožnje ali upravljanja strojev niso opazili.
English: If preferred, you may use one of the plasters (G) provided in the pack to hold the plastic wings of the needle in place at the injection site.
Slovenian: Če želite, lahko uporabite tudi obliž (G) v pakiranju, s katerim plastična krilca igle pritrdite na mestu injiciranja.
English: Pharmacokinetic properties were evaluated in 28 subjects (≥15 years) receiving ELOCTA (rFVIIIFc).
Slovenian: Farmakokinetične lastnosti so ocenili pri 28 osebah (≥ 15 let), ki so dobivale zdravilo ELOCTA
English: ELOCTA should not be mixed with other solutions for injection or infusion.
Slovenian: Zdravila ELOCTA ne smete mešati z drugimi raztopinami za injiciranje ali infundiranje.
English: In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma activity level (in % of normal or IU/dL) in the corresponding period.
Slovenian: V primeru spodaj navedenih krvavitev aktivnost faktorja VIII ne sme pasti pod navedeno raven aktivnosti v plazmi (v % normalne vrednosti ali i.e./dl) v ustreznem obdobju.
English: Subjects that switched from on-demand treatment to weekly prophylaxis during Study III had a median ABR of 1.67.
Slovenian: Osebe, ki so prešle z režima zdravljenja po potrebi na tedensko profilakso med študijo III, so imele mediano letne stopnje krvavitev 1,67.
English: Discard any unused solution appropriately.
Slovenian: Vso neuporabljeno raztopino ustrezno zavrzite.
English: Therefore, it is recommended to monitor all patients carefully for inhibitor occurrence following any product switch.
Slovenian: Zato se priporoča skrbno spremljanje pojava inhibitorjev pri vseh bolnikih, ki zamenjajo zdravilo.
English: It is strongly recommended that every time ELOCTA is given, the name and batch number of the product are recorded.
Slovenian: Močno se priporoča, da se vsakič pri dajanju zdravila ELOCTA zabeležita ime zdravila in številka serije.
English: Dose based on bodyweight may require adjustment in underweight and overweight patients.
Slovenian: Odmerek na osnovi telesne mase bo morda treba prilagoditi pri bolnikih s premajhno ali preveliko telesno maso.